WO2005095586A1 - 不凍糖タンパク質誘導体を含有する細胞凍結保存用組成物 - Google Patents
不凍糖タンパク質誘導体を含有する細胞凍結保存用組成物 Download PDFInfo
- Publication number
- WO2005095586A1 WO2005095586A1 PCT/JP2005/005812 JP2005005812W WO2005095586A1 WO 2005095586 A1 WO2005095586 A1 WO 2005095586A1 JP 2005005812 W JP2005005812 W JP 2005005812W WO 2005095586 A1 WO2005095586 A1 WO 2005095586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- composition
- formula
- cell
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
Definitions
- the present invention relates to a composition for cryopreserving mammalian cells, a solution containing the composition, and a preservation method.
- Cryopreservation technology which preserves living cells semi-permanently while living, is currently used to preserve blood cells for blood transfusion, preserve bone marrow cells and living tissues for bone marrow transplantation and organ transplantation, artificial insemination and genetics. It is being widely used for preserving sperm and fertilized eggs for preserving resources.
- the rate of functional recovery of living tissues after thawing is not high, and there is a need for the development of more desirable preservation techniques.
- Non-Patent Document 1 reports a macromolecular antifreeze compound in blood, and this macromolecular antifreeze compound is currently called “antifreeze glycoprotein” (AFGP).
- AFGP antifreeze glycoprotein
- Patent Document 1 describes a method for protecting and preserving living cells using a heat hysteresis protein extracted from fish, but this effect is based on the interaction with the heat hysteresis protein and cells and cell membranes. And is independent of its effect on the propagation of ice (propagatior).
- Non-Patent Document 2 and Patent Document 2 do not specifically describe the effect of preserving a force cell, tissue, organ, or the like, which describes the AFGP derivative or the method for producing the same according to the present invention.
- Non-Patent Document 1 Science, 163, p. 1073-1075 (1969)
- Non-Patent Document 2 Angeuvante Chemie International Edition (
- Patent Document 1 International Publication WO91Z10361 pamphlet
- Patent document 2 International publication WO00Z09546 pamphlet
- An object of the present invention is to provide a technique for long-term cryopreservation of mammalian cells, tissues or organs without deteriorating the feasibility.
- the present invention provides
- the present invention relates to the following (2) to (8).
- the compound represented by the formula (I), wherein n is one kind selected from 2 to 10, a salt thereof, or a composition containing only a solvate thereof, is substantially free from impurities.
- the impurities include components other than AFGP, which are mixed when extracting AFGP from fish or the like, proteins derived from organisms that may adversely affect the human body such as antigenicity, and viruses derived from organisms.
- a compound represented by the formula (I) selected, a salt thereof or a solvate thereof, and two or more compounds represented by the formula (I) selected from 2 to 10 different from n described above, a salt thereof or A composition comprising a mixture of these solvates and substantially free of impurities is meant.
- the impurities include components other than AFGP, which are mixed when extracting AFGP from fish and the like, proteins derived from organisms that may adversely affect the human body, such as antigenicity, and viruses derived from organisms. Include.
- composition according to (1) which is:
- composition according to (1) wherein the cells are in the form of mammalian cells or tissues or organs.
- Equation (6)
- a method for cryopreserving cells comprising contacting a cell with a compound represented by the formula (1), a salt thereof, or a solvate thereof.
- a method for cryopreserving cells comprising:
- composition of the present invention makes it possible to cryopreserve cells for a long period of time.
- the preserved cells maintain their functions at a high level with minimal cell damage. Therefore, cells, tissues or organs preserved using the composition of the present invention can be suitably used for transplantation and the like even after thawing, and can prevent or improve tissue damage and organ damage after transplantation. It is possible.
- FIG. 1 is a fluorescence micrograph of splenic islets after cryopreservation.
- FIG. 2 is a micrograph of erythrocytes after cryopreservation.
- FIG. 3 shows the results of measuring the absorbance of the supernatant after cryopreservation.
- FIG. 4 is a micrograph of splenic islets after cryopreservation.
- FIG. 5 is a fluorescence micrograph of splenic islets after cryopreservation.
- cells include animal cells and plant cells, and are preferably mammalian cells.
- mammal means a warm-blooded mammal, including humans, pigs, and sea lions.
- the “cells” in the present specification may be in the form of a tissue or an organ by assembling a plurality of them.
- mammalian “cells” include spleen islets, hepatocytes, leukocytes, Cells such as erythrocytes, platelets, oocytes and embryos, tissues such as skin tissue, bone marrow tissue and corneal tissue, and organs such as spleen, liver, brain, lung, heart, stomach, kidney, spleen, ovary and testis Includes
- “Cryopreservation” includes freezing and preserving cells, organs or tissues by slow freezing, quick freezing, vitrification freezing, or the like.
- the storage temperature is preferably 20 ° C or lower, more preferably 70 ° C or lower, and most preferably 80 ° C to 1200 ° C.
- the compound (I) includes pharmaceutically acceptable salts thereof, for example, salts of mineral acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, and hydrobromic acid; formic acid, acetic acid, Salts of organic acids such as tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, conodic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid and camphorsulfonic acid; Salts of organic bases such as ammonium, trimethylammonium, and triethylammonium; salts of alkali metals such as sodium and potassium, and salts of alkaline earth metals such as calcium and magnesium.
- mineral acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, and hydrobromic acid
- Compound (I) also includes a solvate thereof, and one molecule of compound (I) may be coordinated with an arbitrary number of solvent molecules.
- n in compound (I) is an integer of 2 or more, it can be suitably used in the present invention, but is preferably 4 or more, more preferably 5 or more.
- the upper limit is not particularly limited, but is preferably 50 or less, more preferably 15 or less, further preferably 10 or less, and most preferably 8 or less.
- the weight average molecular weight is preferably at least 1.2 kDa, more preferably at least 2 kDa, even more preferably at least 3 kDa.
- the upper limit is not particularly limited, but is preferably 40 kDa or less, more preferably 15 kDa or less, more preferably 7 kDa or less, and most preferably 5 kDa or less.
- the lower limit of the number average molecular weight is preferably 1.5 kDa or more, more preferably 2.8 kDa or more, and the upper limit is preferably 5 kDa or less, more preferably 4 kDa, and still more preferably 3.5 kDa.
- Preferred examples of the compound (I) include the following compounds.
- compositions, shape and the like of the composition of the present invention are not particularly limited as long as it contains compound (I).
- Compound (I) may be used alone in any case.R 1 and Z or n are different. May be used in combination.
- the shape of the composition may be a deviation such as a powder, granules, or solution.
- the composition can be prepared by mixing with various additives and solvents that are generally used in addition to compound (I).
- the solution of the present invention is not particularly limited as long as it contains the composition of the present invention.
- the solution of the present invention is added to a preservation solution or a reflux solution clinically used for preserving tissues and organs. It is obtained by doing.
- the preservation or reflux solutions used clinically include physiological saline, Ringer's solution, Collins solution, Eurocollins solution, UW solution, PFC (perfluorocarbon) emulsion, dimethylsulfoxide (DMSO) solution, Glycerin solution and the like. Particularly preferred is a DMS O solution.
- the solution of the present invention can be obtained by adding the composition of the present invention to the above-mentioned stock solution or reflux solution.
- concentration of compound (I) in the solution of the present invention depends on the type of cells, organs or tissues, storage conditions, the type of storage or reflux solution, and the types and concentrations of other additives.
- z gZml ⁇ It can be changed appropriately within the range of LOmgZml.
- the lower limit of the concentration is preferably at least 0.5 / z gZml, more preferably at least 0.5 / z gZml, and most preferably at least 1 / z gZml.
- the upper limit of the concentration is preferably lmgZml or less, more preferably 800 ⁇ gZml or less, and most preferably less than 500 ⁇ gZml.
- additives such as commonly used intracellular protective agents and vitrifying agents may be added.
- intracellular protective or vitrifying agents examples include DMSO, glycerin, propylene glycol, ethylene glycolone, gnorecose, sucrose, torenodulose, propanediole, butanediol, carboxymethylcellulose or its salts, and polypyrrolidone. No.
- the concentration of the intracellular protective agent or vitrification agent is, for example, in the range of 0.01 mmol / ml to 20 mmol / ml, depending on the type, the type of cell, organ or tissue, storage conditions, and the concentration of the conjugate (I). It can be changed as appropriate.
- the lower limit of the concentration is preferably at least 0.5 mmol Zml, more preferably at least 0.5 mmol Zml, most preferably at least I mmol Zml.
- the upper limit of the concentration is preferably 10 mmol Zml or less, more preferably 5 mmol Zml or less, and Is also preferably 2 mmol Zml or less.
- the cells When storing the cells, the cells may be suspended in the solution of the present invention and then frozen.
- the cells When the cells are in the form of tissues or organs, it is preferable to freeze the cells after immersing or refluxing them for a certain period of time in order to sufficiently bring the solutions of the present invention into contact with the tissues or organs. For example, it may be frozen by slow freezing, rapid freezing, vitrification freezing, etc. after several minutes to several hours while immersing or refluxing under the conditions of 0 to 10 ° C.
- AFGP from which natural product power is also extracted, contains impurities such as proline. If a preservation solution containing natural AFGP is used, it may cause cell damage to cells, tissues or organs during storage or thawing. Become. However, since the composition of the present invention uses compound (I) which is a synthetic AFGP having high purity, the influence of impurities can be minimized.
- compound (I) can be produced in large quantities by chemical synthesis, and it is possible to prepare a large amount of the composition of the present invention at low cost.
- a compound having a weight average molecular weight of 4690 and a number average molecular weight of 3000 was used to examine the viability after cryopreservation of splenic islets.
- the spleen of an 8-week-old Wistar rat was digested by a collagenase perfusion method (Worthington TypelV collagenase O.09%) using total bile duct force-urification.
- the spleen islets were isolated by specific gravity centrifugation using Ficoll-Conray (FicoU-Conray) solution (manufactured by Amersham Bioscience).
- the spleen islets were cultured overnight in RPMI1640 (Sigma (Sigma)) 10% FCS medium to recover from cell injury during the isolation process, and then used for freezing experiments.
- spleen islets were frozen in 200 1 of the following freezing medium. (DMSO and RPMI1640: Sigma)
- Freezing was performed using a program freezer CryoEmbryo (manufactured by HOXAN) using a slow freezing program.
- Freezing program seeding at 5.5 ° C, freezing to 80 ° C at 0.3 ° C / min, and storing in liquid nitrogen (gas phase)
- the results of PI / FDA staining are shown in FIG.
- the addition group of DMS01M alone was stained red, and the group of DMS01M and synthetic AFGP added at 1 ⁇ g / ml was stained yellow-green. In the latter, a clear effect of maintaining the spleen islet shape after thawing was observed.
- Table 1 below shows the results of the viability evaluation by PI / FDA staining as the viable cell rate (FDA positive rate / FDA positive rate + PI positive rate).
- Test Example 1 The same compound as in Test Example 1 was used as the synthetic AFGP to determine the morphology and degree of hemolysis after cryopreservation of red blood cells! I studied.
- FIGS. As is evident from FIG. 2, morphologically, the red blood cell morphology after thawing was maintained in a concentration-dependent manner in the group to which the synthetic AFGP was added. In addition, as apparent from FIG. 3, the degree of hemolysis was low in a concentration-dependent manner in the group to which the synthetic AFGP was added.
- rat spleen islets with a diameter of 100 to 200 m isolated by collagenase digestion were used in Test Example 1 in 2 M DMSO RPMI 1640 + 10% FCS medium in 1.5 ml cryotubes (Nunk).
- the synthesized AFGP was stored at a concentration of 0 or 500 g / ml.
- freezing use a program freezer at a freezing rate of -0.3 ° C / min, inoculate at -5.5 ° C, freeze to -40 ° C, and then store in liquid nitrogen gas phase. . After storing for 1 week, it was quickly thawed at 200 ° C / min. After serial dilution with 0.75 MSucrose RPMI1640 + 10% FCS, centrifugation, and removal of supernatant, RPMI1640 + 10% FCS medium in the presence of 5% CO at 37 ° C for 24 hours
- the culture was continued for a while. After culturing for 24 hours, the number of spleen islets with a diameter of 10 or more was counted.
- the number of spleen islets after freeze-thawing was preserved at an AFGP concentration of 500 g / ml.
- FIGS. 4 and 5 show photographs of splenic islet cells at a synthetic AFGP concentration of 0,500 g / ml and PI staining results 24 hours after freezing and thawing.
- rat splenic islets were frozen and thawed.
- 50 rat spleen islets having a diameter of 100 to 200 ⁇ m were picked up by hand under a stereomicroscope, and washed with 2.8 mM Glucose (basal) Krebs-Ringer Bicarbonate Buffer (KRB).
- KRB Krebs-Ringer Bicarbonate Buffer
- Preculture was performed for 1 hour in the presence of C, 5% C02. Thereafter, the medium was replaced with 2.8 mM glucose (basal) KRB, and after culturing for 1 hour, the supernatant was recovered. Further, after the medium was replaced with 16.7 mM glucose (stimulation) KRB and the cells were cultured for 1 hour, the supernatant was recovered.
- the insulin concentration in each of the collected supernatants was measured by ELISA, and the Static stimulation index was calculated. Table 3 shows the results.
- the freezing process of the spleen islets in a solution to which various concentrations (0 or 500 ⁇ g / ml) of the synthetic AFGP was added was observed under a cryomicroscope (Olympus) and recorded in a video.
- the results showed that in the test with an AFGP concentration of 500 g / ml, the effect of inhibiting ice crystal formation was highly effective in preventing spleen islet destruction during freezing.
- composition is useful as a composition for long-term cryopreservation without reducing the viability of mammalian cells, tissues or organs.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-102396 | 2004-03-31 | ||
JP2004102396 | 2004-03-31 | ||
JP2004-283680 | 2004-09-29 | ||
JP2004283680 | 2004-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005095586A1 true WO2005095586A1 (ja) | 2005-10-13 |
Family
ID=35063773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005812 WO2005095586A1 (ja) | 2004-03-31 | 2005-03-29 | 不凍糖タンパク質誘導体を含有する細胞凍結保存用組成物 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005095586A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011504107A (ja) * | 2007-11-21 | 2011-02-03 | ロスキレ ユニバーシティ | 氷結合活性を備えたポリペプチド |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010361A1 (en) * | 1990-01-17 | 1991-07-25 | The Regents Of The University Of California | Composition to improve survival of biological materials |
WO2000009546A1 (fr) * | 1998-08-10 | 2000-02-24 | Hokkaido Electric Power Company, Incorporated | Preparation de glycopeptides ordinaires |
-
2005
- 2005-03-29 WO PCT/JP2005/005812 patent/WO2005095586A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010361A1 (en) * | 1990-01-17 | 1991-07-25 | The Regents Of The University Of California | Composition to improve survival of biological materials |
WO1992012722A1 (en) * | 1990-01-17 | 1992-08-06 | The Regents Of The University Of California | Antifreeze glycopeptide compositions to protect cells and tissues during freezing |
WO2000009546A1 (fr) * | 1998-08-10 | 2000-02-24 | Hokkaido Electric Power Company, Incorporated | Preparation de glycopeptides ordinaires |
Non-Patent Citations (5)
Title |
---|
ABE Y. ET AL.: "Futo Tanpakushitsu ni yoru Ushi Miseijuku Ranshi no Glass-ka Hozonho no Kairyo.", SHOKUNIKU NI KANSURU JOSEI KENKYU CHOSA SEIKA HOKOKUSHO, vol. 22, December 2004 (2004-12-01), pages 21 - 24, XP002992665 * |
ARAI S. ET AL.: "Koso Shushoku Tanpakushitsu no Toketsu Boshi Koka to sono Oyo.", CRYOBIOLOGY AND CRYTECHNOLOGY, vol. 40, no. 1, 1994, pages 13 - 18, XP002992663 * |
BEN R. ET AL.: "Antifreeze Glycoproteins.Preventing the Growth of Ice.", CHEM.BIO.CHE., vol. 2, no. 3, 2001, pages 161 - 166, XP002992661 * |
MATSUMOTO S. ET AL.: "Gosei Futoto Tanpakushitsu o mochiita Suito Toketsu Hozonho no Kaihatsu.", SAISEI IRYO, vol. 4, 10 February 2005 (2005-02-10), pages 150, XP002992664 * |
TANAKA M. ET AL.: "uto Tanpakushitsu.", BIOPHYSICS, vol. 43, no. 3, 2002, pages 130 - 135, XP002992662 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011504107A (ja) * | 2007-11-21 | 2011-02-03 | ロスキレ ユニバーシティ | 氷結合活性を備えたポリペプチド |
JP2014113164A (ja) * | 2007-11-21 | 2014-06-26 | Roskilde Univ | 氷結合活性を備えたポリペプチド |
US8859230B2 (en) | 2007-11-21 | 2014-10-14 | Roskilde Universitet | Polypeptides comprising an ice-binding activity |
US9241511B2 (en) | 2007-11-21 | 2016-01-26 | Roskilde Universitet | Polypeptides comprising an ice-binding activity |
US10266576B2 (en) | 2007-11-21 | 2019-04-23 | Roskilde Universitet | Polypeptides comprising an ice-binding activity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stolzing et al. | Hydroxyethylstarch in cryopreservation–Mechanisms, benefits and problems | |
CN110050782B (zh) | 一种干细胞冻存液及其制备方法和冻存方法 | |
Scott et al. | Biopreservation of red blood cells: past, present, and future | |
US20190059360A1 (en) | Cryopreservation of cells in absence of vitrification inducing agents | |
RU2396748C2 (ru) | Среда для хранения клеток | |
CN108207930A (zh) | 一种鸡尾酒式冷冻保护剂及其应用 | |
WO2014162910A1 (ja) | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 | |
Rajan et al. | Development and application of cryoprotectants | |
JP5773347B2 (ja) | 血液細胞の凍結保存剤 | |
JPH089521B2 (ja) | 極洋の魚類から単離および精製された熱ヒステリシスタンパク質 | |
Taylor et al. | A new preservation solution for storage of corneas at low temperatures | |
EP3487296A1 (en) | Enhancement of cell cryopreservation with glycolipids | |
JP7038369B2 (ja) | ウシ生殖細胞の凍結保存用組成物及び凍結保存方法 | |
JP2022528772A (ja) | Dmsoフリーの凍結保存液及びその調製方法と応用 | |
AU2009329909B2 (en) | Apparatus and method for the preservation of pancreatic tissue and islet cells for transplantation | |
US20100167260A1 (en) | Use of N-Piperidine Derivative Compositions for Protecting Biological Systems | |
ES2949014T3 (es) | Uso de una disolución que comprende PEG para la conservación de células madre | |
Brockbank et al. | Storage of tissues by vitrification | |
CN107372469A (zh) | 一种内皮祖细胞的冻存液及冻存方法 | |
WO2005095586A1 (ja) | 不凍糖タンパク質誘導体を含有する細胞凍結保存用組成物 | |
Halberstadt et al. | Corneal cryopreservation with dextran | |
EP2593116B1 (en) | Methods for increasing isolation yields of cellular products | |
JP2010248160A (ja) | 細胞延命効果を有するペプチド | |
US11998002B2 (en) | Cryopreserving processes | |
RU2785227C1 (ru) | Криоконсервирующий раствор, не содержащий дмсо, и способ его получения и применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |